Shares of Humana (HUM) surged 5.26% in pre-market trading on Wednesday after the health insurance giant reported better-than-expected first-quarter earnings and reaffirmed its full-year guidance, despite ongoing challenges in the Medicare Advantage market.

The Louisville, Kentucky-based company posted adjusted earnings per share of $11.58 for Q1 2025, significantly surpassing analysts' expectations of $10.07. While revenue came in slightly below estimates at $32.11 billion compared to the projected $32.22 billion, investors appeared to focus on the strong bottom-line performance.

Humana's medical loss ratio, a key metric measuring the percentage of premiums spent on medical care, stood at 87.4% for the quarter, in line with the company's previous estimate and slightly better than analysts' forecast of 87.5%. This indicates that the insurer has been effectively managing its healthcare costs.

In a move that further bolstered investor confidence, Humana reaffirmed its full-year 2025 adjusted earnings guidance of approximately $16.25 per share. The company also maintained its forecast for the insurance segment's benefit ratio, projecting it to be between 90.1% and 90.5% for the year.

Humana President and CEO Jim Rechtin expressed optimism about the company's performance, stating, "Medicare Advantage is performing as expected and we are excited about our progress in expanding CenterWell and Medicaid." This positive outlook, combined with the strong quarterly results, appears to have alleviated some investor concerns about the challenges facing the Medicare Advantage market.

The pre-market stock surge suggests that investors are reassured by Humana's ability to navigate the current healthcare landscape and maintain its financial targets despite industry headwinds. As the market opens, all eyes will be on whether this early momentum can be sustained throughout the trading day.